These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 32829399)
1. Herpes Zoster and Postherpetic Neuralgia: Changing Incidence Rates From 1994 to 2018 in the United States. Thompson RR; Kong CL; Porco TC; Kim E; Ebert CD; Acharya NR Clin Infect Dis; 2021 Nov; 73(9):e3210-e3217. PubMed ID: 32829399 [TBL] [Abstract][Full Text] [Related]
2. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan. Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019 [TBL] [Abstract][Full Text] [Related]
3. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400 [TBL] [Abstract][Full Text] [Related]
4. Increasing incidence associated with herpes zoster infection in British Columbia, Canada. Marra F; Chong M; Najafzadeh M BMC Infect Dis; 2016 Oct; 16(1):589. PubMed ID: 27765026 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Pellissier JM; Brisson M; Levin MJ Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938 [TBL] [Abstract][Full Text] [Related]
6. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study. Schmidt-Ott R; Schutter U; Simon J; Nautrup BP; von Krempelhuber A; Gopala K; Anastassopoulou A; Guignard A; Curran D; Matthews S; Espié E J Infect; 2018 May; 76(5):475-482. PubMed ID: 29428228 [TBL] [Abstract][Full Text] [Related]
7. Herpes zoster and postherpetic neuralgia in Catalonia (Spain). Salleras L; Salleras M; Salvador P; Soldevila N; Prat A; Garrido P; Domínguez A Hum Vaccin Immunother; 2015; 11(1):178-84. PubMed ID: 25483532 [TBL] [Abstract][Full Text] [Related]
9. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia. Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817 [TBL] [Abstract][Full Text] [Related]
10. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. Langan SM; Smeeth L; Margolis DJ; Thomas SL PLoS Med; 2013; 10(4):e1001420. PubMed ID: 23585738 [TBL] [Abstract][Full Text] [Related]
11. Incidences of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged 50 Years and Older From a Community-based Prospective Cohort Study: The SHEZ Study. Takao Y; Miyazaki Y; Okeda M; Onishi F; Yano S; Gomi Y; Ishikawa T; Okuno Y; Mori Y; Asada H; Yamanishi K; Iso H J Epidemiol; 2015; 25(10):617-25. PubMed ID: 26399445 [TBL] [Abstract][Full Text] [Related]
12. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination. Johnson RW Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648 [TBL] [Abstract][Full Text] [Related]
13. Herpes zoster: treatment, management, and prevention with the recombinant DNA vaccine. Li E; Closmann JJ; Jordan RC Gen Dent; 2024; 72(1):54-57. PubMed ID: 38117642 [TBL] [Abstract][Full Text] [Related]
14. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. Schmader K; Gnann JW; Watson CP J Infect Dis; 2008 Mar; 197 Suppl 2():S207-15. PubMed ID: 18419399 [TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States. Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143 [TBL] [Abstract][Full Text] [Related]
17. Vaccination against herpes zoster in developed countries: state of the evidence. Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598 [TBL] [Abstract][Full Text] [Related]
18. A population based study of the epidemiology of Herpes Zoster and its complications. Weitzman D; Shavit O; Stein M; Cohen R; Chodick G; Shalev V J Infect; 2013 Nov; 67(5):463-9. PubMed ID: 23872209 [TBL] [Abstract][Full Text] [Related]
19. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. Gialloreti LE; Merito M; Pezzotti P; Naldi L; Gatti A; Beillat M; Serradell L; di Marzo R; Volpi A BMC Infect Dis; 2010 Aug; 10():230. PubMed ID: 20682044 [TBL] [Abstract][Full Text] [Related]
20. Incidence of Herpes Zoster and Postherpetic Neuralgia and Herpes Zoster Vaccination Uptake in a US Administrative Claims Database. Marcum ZA; Jain P; Embry A; Arakaki B; Estevez I; Viscidi E Open Forum Infect Dis; 2024 May; 11(5):ofae211. PubMed ID: 38737423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]